

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Anthelmin 230 mg/20 mg film-coated tablets for cats

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

#### **Active substances:**

Each film-coated tablet contains:

Pyrantel embonate 230 mg (equivalent to 80 mg pyrantel)

Praziquantel 20 mg

#### **Excipients:**

| <b>Qualitative composition of excipients and other constituents</b> |
|---|
| Maize starch  |
| Povidone K25  |
| Cellulose, microcrystalline (E460)                                  |
| Silica, colloidal anhydrous   |
| Magnesium stearate (E572)   |
| Hypromellose  |
| Macrogol 4000   |
| Titanium dioxide (E171)   |

White to almost white, biconvex, oval film-coated tablet, scored on one side.  
The tablet can be divided into halves.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Cats.

### 3.2 Indications for use for each target species

For the treatment of mixed infestations with roundworms, hookworms and tapeworms in cats, caused by:

- Ascarids (roundworms): *Toxocara cati* (adults)
- Hookworms: *Ancylostoma tubaeforme* (adults), *Ancylostoma braziliense* (adults)
- Cestodes (tapeworms): *Echinococcus multilocularis*, *Dipylidium caninum*, *Hydatigera (Taenia) taeniaeformis*, *Mesocestoides* spp., *Joyeuxiella pasqualei*.

### 3.3 Contraindications

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

Please see section 3.7 and section 3.8.

### 3.4 Special warnings

Tapeworm infestation occurs in cats at the earliest in the third week of life.

Fleas serve as intermediate hosts for one common type of tapeworm – *Dipylidium caninum*.

Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc. is undertaken.

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, this may be due to underestimation of body weight or misadministration of the veterinary medicinal product.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species

Not applicable.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental ingestion, seek medical advice and show the package leaflet to the physician.

In the interest of good hygiene, persons administering the tablets directly to the cat or by adding them to the cat's food, should wash their hands afterwards.

Unused part-tablets should be returned to the open blister pocket and kept in a safe place out of the sight and reach of children.

#### Special precautions for the protection of the environment

Not applicable.

### Other precautions

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

### **3.6 Adverse events**

Cats:

|  |  |
|--|--|
| Very rare<br>(<1 animal / 10,000 animals treated, including isolated reports): | Digestive tract disorders (e.g. hypersalivation and/or vomiting)*<br>Neurological disorders (e.g. ataxia)* |
|--|--|

\*Mild and transient.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy:

The safety of the veterinary medicinal product has not been established during pregnancy.

Do not use during pregnancy.

#### Lactation:

Can be used during lactation.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Do not use simultaneously with piperazine compounds, because the specific activities of piperazine (neuromuscular paralysis of the parasites) can inhibit the efficacy of pyrantel (spastic paralysis of the parasites).

### **3.9 Administration routes and dosage**

Oral use. Single administration.

To ensure administration of a correct dose, body weight should be determined as accurately as possible.

#### *Dosage:*

5 mg praziquantel and 20 mg pyrantel base (57.5 mg pyrantel embonate) per kg of body weight. This corresponds to 1 tablet per 4 kg of body weight.

| Body weight  | Tablets |
|--------------|---------|
| 1.0 - 2.0 kg | 1/2     |
| 2.1 - 4.0 kg | 1       |
| 4.1 - 6.0 kg | 1 1/2   |
| 6.1 - 8.0 kg | 2       |

Kittens weighing less than 1 kg should not be treated with the veterinary medicinal product, because correct dosing of such cats may not be feasible.

*Route of administration:*

The tablets are to be given directly into the mouth but can be administered in a small amount of food, if necessary.

*Note:*

In ascarid infestation, especially in kittens, complete elimination cannot be expected, so a risk of infection for humans can persist. Repeat treatments should therefore be carried out with a suitable roundworm veterinary medicinal product at 14 day intervals until 2-3 weeks after weaning.

If signs of disease persist or appear, consult a veterinary surgeon.

**3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

Symptoms of overdoses do not occur less than 5 times the recommended dose. The first expected sign of intoxication is vomiting.

**3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

**3.12 Withdrawal periods**

Not applicable.

**4. PHARMACOLOGICAL INFORMATION**

**4.1 ATCvet code: QP52AA51**

**4.2 Pharmacodynamics**

The veterinary medicinal product is a roundworm and tapeworm anthelmintic containing as active constituents the pyrazinoisoquinolinone derivative praziquantel and the tetrahydropyrimidine derivative pyrantel (as embonate salt).

In this fixed combination praziquantel serves as a tapeworm agent whose action spectrum covers cestode species in cats, in particular *Hydatigera (Taenia) taeniaeformis*, *Joyeuxiella pasqualei*., *Dipylidium caninum*, *Mesocostoides* spp. and *Echinococcus multilocularis*. Praziquantel acts against all stages of these parasites occurring in the cat intestine.

Pyrantel is the roundworm-specific component and has a good activity against nematodes occurring in cats, in particular *Toxocara cati*, and *Ancylostoma tubaeformae* and *Ancylostoma braziliense*. Pyrantel acts as a cholinergic agonist similarly to nicotine, and causes spastic paralysis of the nematodes by a depolarising neuromuscular blockade.

Praziquantel is absorbed very rapidly through the parasite's surface and is distributed evenly inside the parasite. Both in vitro and in vivo severe damage to the parasite integument sets in very quickly, resulting in contraction and paralysis of the parasites. The basis for the rapid onset of action is above all the praziquantel-induced change in the permeability of the parasite membrane to  $Ca^{++}$ , which leads to a dysregulation of the parasite metabolism.

#### **4.3 Pharmacokinetics**

Praziquantel is rapidly absorbed following oral administration. Maximum serum levels are achieved within 2 hours. Praziquantel is widely distributed and is rapidly metabolised in the liver. In addition to other metabolites, the main metabolite occurring in each case is the 4-hydroxycyclohexyl derivative of praziquantel. Praziquantel is completely eliminated within 48 hours in the form of its metabolites - between 40 and 71 % in the urine and, in bile, between 13 and 30 % in the faeces.

The embonate salt of pyrantel is poorly absorbed from the gastrointestinal tract..

### **5. PHARMACEUTICAL PARTICULARS**

#### **5.1 Major incompatibilities**

Not applicable.

#### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years  
Shelf life of halved tablets after first opening the immediate packaging: 1 month.

#### **5.3 Special precautions for storage**

Store unused parts of the halved tablets below 25 °C. Each time an unused part-tablet is stored until next use, it should be returned to the open blister pocket and kept in a safe place out of the sight and reach of children.

#### **5.4 Nature and composition of immediate packaging**

Blister packs consisting of cold formed OPA/Aluminium/PVC foil and aluminium foil containing 2 or 10 tablets.

2 x 1, 4 x 1, 10 x 1, 30 x 1, 50 x 1 or 100 x 1 tablet in perforated unit dose blisters, in a box.

Not all pack sizes may be marketed.

#### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

### **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

KRKA, d.d., Novo mesto  
Smarjeska cesta 6  
8501 Novo mesto  
Slovenia

### **7. MARKETING AUTHORISATION NUMBER**

Vm 01656/3054

### **8. DATE OF FIRST AUTHORISATION**

03 April 2017

### **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

October 2023

### **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription. (AT, CZ (packaging for 30, 50, 100 tbl), DE, ES, FI (packaging for 30, 50, 100 tbl), FR (packaging for 30, 50, 100 tbl))

Veterinary medicinal product not subject to prescription.(BE, BG, CZ (packaging for 2, 4, 10 tbl), EE, FI (packaging for 2, 4, 10 tbl), FR (packaging for 2, 4, 10 tbl, HR, HU, IE, IT, LT, LV, NL, PL, PT, RO, SI, SK, UK(NI))

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

Approved 20 October 2023

A handwritten signature in black ink, appearing to read "J. Hunter.", is positioned below the approval date.